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RemodelThe SWI/SNF complex remodels nucleosomes, allowing RNA Polymerase II access to the HIV-1 proviral DNA. It
has not beendeterminedwhich SWI/SNF complex (BAForPBAF) remodels nucleosomes at the transcription start
site. These complexes differ in only three subunits and determining which subunit(s) is required could explain
the regulation of Tat activated transcription. We show that PBAF is required for chromatin remodeling at the
nuc-1 start site and transcriptional elongation.Weﬁnd thatBaf200 is required to ensureactivationat theLTR level
and for viral production. Interestingly, the BAF complex was observed on the LTR whereas PBAF was present on
both LTR and Env regions.We found that Tat activated transcription facilitates removal of histones H2A and H2B
at the LTR, and that the FACT complexmay be responsible for their removal. Finally, the BAF complexmay play an
important role in regulating splicing of the HIV-1 genome.ense and Infectious Diseases,
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Human immunodeﬁciency virus (HIV-1) is shown to become latent
upon infection in T lymphocyte (T cell) (as well as other cell types)
when cell activation has halted and transcription factor levels needed
for both the cell and virus have become dramatically reduced or absent
altogether. HIV-1 latency is especially important in light of the fact that
viral reservoir can reanimate years later and avoid the consequences of
immune clearance or antiviral drugs.
The HIV-1 promoter contains many critical DNA binding sites
including two NF-κB sites, three Sp1-binding sites, and a TATA box. The
activity of the LTR depends on the viral activator Tat which is believed to
function at the level of both initiation and elongation (Bohan et al., 1992;
Feinberg et al., 1991; Kato et al., 1992; Laspia et al., 1989; Marciniak et al.,
1990; Marciniak and Sharp, 1991). It is additionally involved in thestabilization of the TFIID/TFIIA complex on the HIV-1 TATA box
(Kashanchi et al., 1992) and recruitment of a functional TATA-binding
protein (TBP) (Chiang and Roeder, 1995; Dal Monte et al., 1997; Garcia-
Martinez et al., 1997; Kashanchi et al., 1996; Roebuck et al., 1997;
Veschambre et al., 1995). Furthermore, van Opijnen et al. (2004) have
proposed that the HIV-1 promoter contains a CATA box instead of a TATA
box in order to achieve optimal transcription and replication. Tat binds to
and interacts with a number of transcriptional cofactors including Sp1,
cyclin E/cdk2, TFIIH, Tip 60, Pol II and the activators CBP/p300 and p/CAF.
Transcriptional activity from the HIV-1 LTR is restricted in vivo
partially due to the higher order chromatin structure of the HIV-1
proviral DNA. The 5′ LTR contains four distinct DNase I hypersensitive
sites (DHS) (Van Lint et al., 1996; Verdin, 1991; Verdin et al., 1993). It
has been largely assumed that DHS in native chromatin are free of
histones and allow unrestricted access to DNA-binding proteins
(McGhee et al., 1981). Furthermore, independent of the viral integration
site, ﬁve nucleosomes (nuc-0 to nuc-4) are precisely positioned within
the 5′ LTR. In the transcriptionally silent provirus, these nucleosomes
deﬁne two large nucleosome-free regions spanning nucleotides
(nt) −255 to −3 and nt +141 to +265; nuc-1 (which encompasses
the transcription start site) is located between these two regions. The
ﬁrst nucleosome-free region contains many promoter/enhancer ele-
ments which are already occupied by transcription factors (Demarchi
et al., 1993). When cells are activated with tumor necrosis factor alpha
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(i.e., trapoxin, Trichostatin A (TSA), and sodium butyrate) DHS3 and
DHS4 are extended and nuc-1 is speciﬁcally remodeled (Coull et al.,
2002; Demarchi et al., 1993; Simone, 2006). Chromatin immunopre-
cipitation (ChIP) assays suggest that histone acetylation surrounding
nuc-1 signiﬁcantly increases following TSA treatment.
Toovercome thenucleosomalbarrier, post translationalmodiﬁcations,
such as histone acetyltransferases (HATs), can result in the opening or
closing of the chromatin. Additionally chromatin can be remodeled using
the energy fromATPhydrolysis to alter interactions betweenhistones and
DNA allowing increased access to DNA within a nucleosomal array
(Kingston and Narlikar, 1999). The interactions that can occur in both
chromatin assembly and remodeling are very complex and many studies
have recently been published showing the importance of this in HIV-1
transcriptional activation. A recent paper that focuses on the Tat
interactome identiﬁed a number of chromatin remodeling complexes
that interact with Tat including the SWI/SNF, NURD, and FACT (Gautier
et al., 2009). In addition to this study, other labs have further identiﬁed
proteins that directly interact with Tat and act to promote viral
transcription such as the histone chaperone protein Nucleosome
Assembly Protein-I (hNAP-1) (Vardabasso et al., 2008). BAF and PBAF
are both in the SWI/SNF family of chromatin remodeling complexes
which utilize BRG1, or the closely related BRM, as the main catalytic
subunit for ATPase activity (Klochendler-Yeivin et al., 2002; Olave et al.,
2002; Yan et al., 2005). Chromatinmodifying enzymes (i.e., p300/CBP, p/
CAF) can work together with SWI/SNF to facilitate a chromatin structure
that is accessible for the basal transcription machinery (Narlikar et al.,
2002). BRM(Treandet al., 2006) andBRGhavebeen shown tobe involved
in Tat-mediated activation of the HIV-1 LTR (Agbottah et al., 2006;
Bukrinsky, 2006;Mahmoudi et al., 2006; Treand et al., 2006). Depletion of
endogenous host-cell integrase interactor (INI-1; a SWI/SNF component)
and BRG1 by RNAi can abolish Tat-mediated activation. Acetylation of Tat
at lysines 50 and 51 promote its binding to SWI/SNF (Mahmoudi et al.,
2006);however,wehavealso shownthat lysines41, 50, and51are critical
for SWI/SNF binding (Agbottah et al., 2006). INI-1 can also synergizewith
acetylated Tat and p300/CBP at the HIV-1 promoter to activate the LTR
(Mahmoudi et al., 2006). Targeting of BRG1 to the HIV-1 promoter by
transcription factors, such as ATF-3 and HMGA1, has also been
demonstrated (Henderson et al., 2004). BRG1 expression and TSA
treatments of C33A cells (BRG1-deﬁcient) demonstrated that histone
acetylation plays a role inmaintaining a stable association between BRG1
and the chromatin (Hendersonet al., 1995). In the currentmanuscript,we
address the question of which SWI/SNF complex(es) is associated with
HIV-1 LTR and how it might regulate gene expression by modifying the
nucleosome at the transcription start site (nuc-1). Furthermore we show
that some of the histones are removed from this region once Tat activated
transcription takes place from the HIV-1 LTR.
Results
Multiple subunits of BRG1 and its associated complexes are needed for
Tat activated transcription
The evolutionarily conserved SWI/SNF family exists in several
subgroups and it is suggested that these complexes have very different
functions. This canbe seenbygeneknockoutexperiments, inwhich loss of
BRG1, but not BRM, is embryonically lethal. There are many (at least six)
complexes that could potentially associate with BRG1 and form
complexes such as SWI/SNF (BAF and PBAF), WINAC, NCoR, NUMAC,
and mSin3A/HDAC complexes (Fig. 1A). As chromatin remodelers, these
complexes can either act as transcriptional activators, repressors, or both.
For example, NUMAC acts as a transcriptional activator while the
mSin3A/HDAC complex acts as a transcriptional repressor. SWI/SNF
complexes also can act as either repressors or activators (Trotter and
Archer, 2008). BAF and PBAF differ only in a few subunits where BAF
includes Baf250 and PBAF can include Baf200 and Baf180. The BAFcomplex has two forms, A and B where A utilizes BRG1 for its ATPase
energy, and B utilizes BRM. The PBAF complex can exist with (A) or
without (B) the Baf180 subunit (Yan et al., 2005).
To determine which one of these complex(s) was important for
HIV-1 transcription, we used seven siRNAs that covered some of the
critical and unique subunits of the BRG1 associated complexes. We
asked if using siRNAs against speciﬁc subunits to each BRG1 containing
complex could determine signiﬁcance of their activity in transient Tat
activated transcription. We transfected cells with LTR-CAT with LTR-
CAT and a CMV-Tat construct in CEM T-lymphocytes and scored for the
presence of the CAT enzyme after 48 h. Results of such an experiment
are shown in Fig. 1, panel B, where Tat activated transcription showed
optimal activity in these cells (lane 2). Using distinct siRNAs, we found
that the most signiﬁcant suppression of Tat activated transcription was
with siBaf200 (lane 5) in a 48-h transient transfection assay, although
some of the other siBafs including siBaf180 did show some reduced
transcription. Because Baf200 is important for PBAF complex formation
and Baf250 is important for BAF complex, we decided to further titrate
siRNAs against these two subunits in a similar transient transfection
assay. Results in panel C show that a titration of siBaf200 effectively
inhibits Tat activated transcription and further reinforces the signiﬁ-
cance of PBAF complex requirement for Tat activated transcription on
HIV-1 LTR. Finally, we look at the Tat levels in these transfections
(panel D) and by and large, there were minimal alterations in Tat levels
after siRNA transfection. Collectively, these results indicate that, at least
in a transfection setting in T-cells, Baf200 may be important for Tat
activated transcription.Acetylated Tat binds to SWI/SNF PBAF complex
Both BAF and PBAF have similar core subunits including BRG1, actin,
Baf47 (INI1), Baf53, Baf57, Baf60, Baf155, and Baf170. The two complexes
differ only in a few unique subunits where the BAF complex contains
Baf250 and PBAF contains Baf180 and Baf200 (Simone, 2006; Trotter and
Archer, 2008; Yan et al., 2005).Weandothers have previously shown that
Tat can be acetylated at multiple lysines residues leading to altered
interactions between Tat and TAR, p300/CBP, and p/CAF, as well as
activation of viral transcription and replication (Agbottah et al., 2006;
Ariumi et al., 2006; Bukrinsky, 2006;Mahmoudi et al., 2006; Treand et al.,
2006). We then asked if acetylated Tat could speciﬁcally bring down
components of the PBAF complex. For this we utilized a HeLa
phosphocellulose nuclear fraction (0.75 M) that contained both BAF and
PBAF complexes (Yan et al., 2005) at approximately 0.9–1.0 MDa. We
performed GST-Tat pull down experiments with these fractions and
looked for speciﬁc components of either BAF or PBAF complexes. Results
in Fig. 2A show that both acetylated Tat 86 or Tat 101 bound efﬁciently to
Baf200 (component of PBAF) and weakly to Baf250 (component of BAF).
Actin, a component of both BAF and PBAF complexes was present in
acetylated and unmodiﬁed Tat pull down experiments. To rule out the
possibility that BAF or PBAF complexes may indirectly associate with
contaminating DNA, we used ethidium bromide (EtBr), a DNA interca-
lating agent that dissociates proteins from DNA in these GST-pull down
experiments. It is important to note that under these conditions both
Baf200andBRG1boundwithhigherafﬁnity to theacetylatedTat,whereas
Baf250 bound with less efﬁciency to the acetylated Tat and had a
preference for the unmodiﬁed Tat. Finally, we performed another pull
down experiment using wild type Tat 86 and a Tat K50/51 mutant. For
these Western blots we included 1/5 of the input phosphocellulose
nuclear fraction (0.75 M) in thegelsprior to theWesternblot.We than ran
gels, Western blotted with appropriate antibodies and then counted the
bandsusing aphosphoroImager. Results of such anexperiment are shown
in Fig. 2B, where acetylated GST-Tat 86 pull down (lane 3), but not the
50/51 mutant, showed binding to both Baf200 and BRG1. Collectively,
these results imply that acetylated Tat may have more of a preference to
bind to PBAF complex.
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HIV-1 promoter
Wenext used the TZM-bl cell line,which contains an integratedHIV-1
LTR-Luc, to ask whether knockdown of BAF or PBAF speciﬁc subunitscould affect LTR transcription. Cells were transfectedwith no plasmid, Tat
plasmid alone or Tat plus siRNAs against BRG1, Baf250, Baf180, Baf200 or
BRMusingAttractene.After4 daysof transfectioncellswereprocessed for
luciferase activity (Fig. 3A). In general agreement with our previous
ﬁndings, we observed that knockdown of Baf200, but not Baf250,
Fig. 2. Involvement of PBAF complex on HIV-1 activated transcription. A) GST-Tat (wild-type 86 and 101) were puriﬁed over a glutathione column and eluted. To obtain acetylated
Tat, GST-Tat (2 μg) was incubated with p300 and acetyl-CoA (Agbottah et al., 2006), washed, and incubated with HeLa phosphocellulose nuclear fraction (0.75 M, 100 μg) that
contained both BAF and PBAF complexes. Samples were incubated overnight at 4 °C in presence of EtBr (100 ng/ml), washed, bound complexes were run on a SDS/PAGE gel (4–20%)
andWestern blotted for the presence of Baf200, BRG1, Baf250 and actin using speciﬁc antibodies. Lanes 1 and 4, GST; lane 2, wild-type acetylated Tat 86; lane 3, wild type Tat 86; lane
5, wild-type acetylated Tat 101; and lane 6, wild-type Tat 101. B) Similar experiment as panel A, where acetylated Tat 86 and a Tat 50/51 mutant were used for the pull downs. Bar 1
(input) shows quantitative results from theWestern blot of input (20 μg) of HeLa phosphocellulose nuclear fraction (0.75 M); bar 2 shows acetylated GST-Tat 86 pull down and bar 3
is counts from GST-Tat 86 50/51 mutant pull down. Band intensities were obtained using a Molecular dynamics phosphoroImager instrument. Western blots were with antibodies
for Baf200, BRG1, Baf250 and actin.
325R. Easley et al. / Virology 405 (2010) 322–333inhibited Tat transactivation in this system. Next, to be able to distinguish
and better reproduce the difference between the BAF and PBAF
complexes for Tat activated transcription, we used a Baf180 mutant cell
line, HCC1143 (Yan et al., 2005) in transfection assays. Here the mutant
cells have undetectable levels of the Baf180 subunit of PBAF complex but
still have normal Baf200 levels. We transfected these cells with pNL4-3
viral clone and collected supernatants for the detection of virus after days
2, 3 and 4.We additionally used siRNA against Baf200 to determine if it is
required for viral replication in these Baf180mutant cells. Results of these
experiments are shown in Fig. 3B, where HIV RT was present in the
supernatant after 2 days and the levels dramatically dropped after 4 days
with knockdown of Baf200. These results collectively suggest that
efﬁcient complex involved in Tat activated transcription for integrated
LTR and virus production may be a PBAF complex.
Finally, we performed a similar set of experiments in HLM1 cells
where the HIV-1 virus is integrated (one copy) and it contains a triple
mutation in the Tat open reading frame. Virus particles are onlymade in
these cells with the addition of exogenously added Tat. UponFig. 1. BRG1 associated complexes involved in HIV-1 transcription. A) Brahma-related gene-1
including SWI/SNF complexesBAF and PBAFaswell asWINAC,NCoR,mSin3A/HDAC, andNUM
components; Pink: nuclear receptor association; Gold: DNA replication; Light Green: actin-rela
these complexes can either act as transcriptional activators, repressors, or both. B) CEM cells we
siRNA against Baf250, Baf180, Baf200, Caf1, HDAC3, Cam1, or mSin3a (100 nM). Samples wer
extractswas used for each CAT assay. Bottompanel shows theWestern blot from siRNA treated
siBaf250 (lanes 6–8). Upper insert: Western blot of siBaf200 and siBaf250 treated CEM cells (50
three independent experiments. D) Cells treated with various siRNAs were processed after 4
HIV-LTR-CAT, and Flag-Tat 101 (3 μg) construct and 50 μg of total extract were used for Westetransfection of Tat we observed robust viral particle formation in
these cells (Panel C, lane 2). We then transfected ﬁve different siRNAs
into these cells and found both siBRG1 and siBaf200 (and to some level
siBRM) effectively inhibited viral production in these latent cells.
Collectively these experiments, which utilized chromatinized LTR DNA,
indicate that optimal Tat activated transcription requires PBAF complex.
Remodeling of a nucleosome at the transcription start site
We next asked if all or some of the components of the nuc-1 were
physically removed after Tat activated transcription in vivo. To do this we
used latent OM10.1 cells (containing latent wild type virus) where very
little transcription and virus production is observed.Weﬁrst activated the
virus with low levels of the TNF-α followed by chromatin immunopre-
cipitations (ChIPs) of all four core histones. Here the assumptionwas that
TNF-α would start basal transcription leading to formation of the Tat
protein and consequentially enhance activated transcription by the Tat.
DNA from the ChIP assay was then used for PCR using primers thator (BRG1) is a catalytic subunit found in a variety of chromatin remodeling complexes
AC. Thevarious complexes share other subunits that have a variety of activities:Green: core
ted complexes; Blue: Ini1/Baf47/SNF5; Purple: other functions. As chromatin remodelers,
re transfected (electroporation)with HIV-LTR-CAT (5 μg), CMV-Tat (3 μg), andwith either
e incubated for 48 h and subsequently processed for CAT assay. Fifty micrograms of total
cells. C) Similar to Panel B,with titration (50, 100, and 150 nM) of siBaf200 (lanes 3–5) and
μg of total extract) after 48 h. Experiments in panel B and C are average representative of
8 h and Western blot with anti-Flag antibody. Cells, as in panel B, were transfected with
rn blot.
Fig. 3. Importance of Baf200 in Tat transactivation and HIV-1 viral production. A) Effect of knockdown of BAF or PBAF components on Tat transactivation. TZM-bl cells containing an
integrated HIV-1 LTR-luciferase reporter construct were transfected with either no plasmid, Tat plasmid (0.5 μg), or siRNA for BRG1, Baf250, Baf180, Baf200 or Scr (luciferase
scrambled) (75 nM). Luciferase levels were determined on day 4. Cells at day 4 were processed for Westerns using various Baf and actin antibodies (lower insert). B) Baf180 mutant
cell lines (HCC1143) were transfected with pNL4-3 (20 μg) either alone or with siBaf200 (75 nM). Supernatants were collected for presence of virus in days 2, 3 and 4. Cells (day 4)
were also processed forWesterns using Baf200 and actin antibodies (lower insert). C) HLM-1 cells (containing wild type virus with amutation in Tat) were transfected with CMV-Tat
(3 μg) either alone or in combination with various siRNAs (75 nM). Supernatants were collected at day 4 and used for RT assay. Cells were processed for Western blots after 4 days.
Experiments in all panels were performed at least three times.
326 R. Easley et al. / Virology 405 (2010) 322–333spanned the nuc-0, nuc-1 and the Envelope (Env) region. As seen in Fig. 4
(panel A) viral activation by TNF-α made very little changes in the
composition of the nuc-0 histones (upstream of the transcription
start site). We saw no changes in the H3 or H4 levels on the DNA before
or after viral induction, and only minor changes for H2A and H2B.
However, we observed almost a complete removal of H2A and H2B
proteins from the nuc-1 region after transcriptional activation (middle
insert). Interestingly, we did not see a change in the downstream
nucleosomes including the Env region even after induction of transcrip-
tion (bottom insert). These results collectively point to a scenario whereactivated transcriptionmay in factmodify thenuc-1histones by removing
both histones H2A and H2B thereby “loosening” nucleosomes for Tat
activated transcription. This seems plausible since the removal of histones
from DNA immediately downstream of transcription start site has been
shown to be involved in transcriptional elongation. In fact, removal of
histones H2A andH2B has been seen by the Reinberg lab in an elongation
complex called the FACT (facilitates chromatin transcription) complex
(Orphanides et al., 1998).
We next asked if the FACT complex was associating with the HIV-1
LTR at the nuc-1 region. FACT was initially isolated from extracts that
Fig. 4. Remodeling of the nucleosome on the HIV-1 promoter. A) ChIP assays of four core histones were performed from TNF-α-induced OM10.1 cells. ChIP assays were performed
using H2A, H2B, H3 and H4 antibodies (10 μg ab/reaction). OM10.1 cells (a total of 5×107) were induced with TNF-α (10 ng/ml) for 2 h and subsequently plated for 24 h. Speciﬁc
DNA sequences in the immunoprecipitates were detected by PCR, using primers speciﬁc for HIV-1 LTR nuc-0 (−415 to−255), HIV-1 LTR nuc-1 (+10 to +165) and Env (+8990
to +9120). The HIV-1 proviral DNA in OM10.1 cells was derived from clade B LAI strain. B) Similar to panel A (ChIP assay from OM10.1 cells), except using antibodies against H2A,
FACT, and Pol II. Antibody against the Spt16 subunit of FACT was used for ChIP assay. C) HLM-1 cells were transfected with control empty vector (3 μg) and with CMV-Tat (3 μg) for
48 h. Samples were processed for ChIP assay using antibodies (10 μg/reaction) against H2A, FACT, and Pol II. Recovered DNA was processed for qPCR. Enriched DNA was quantiﬁed
using an ABI Prism 7100 instrument and SYBR green (Applied Biosystems) and normalized to control empty vector HLM-1 cells. Results for FACT qPCR were similar in presence or
absence of Tat. Values are average of three independent experiments.
327R. Easley et al. / Virology 405 (2010) 322–333supported transcription on chromatinized templates (Orphanides et al.,
1998). In humans FACT consists of the proteins Spt16 and the HMG-box
containing SSRP1 (structure speciﬁc recognition protein-1) which are
both highly conserved. FACT is known to contain histone chaperone
activity, suggesting that it functions to re-establish disassembled
nucleosomes (Belotserkovskaya et al., 2003; Orphanides et al., 1999).
In yeast, inactivation of FACT results in transcriptional initiation from
cryptic initiation sites within the coding region of genes, implying thatFACT is required for maintaining chromatin structure in vivo (Reinberg
and Sims, 2006). To asses if HIV-1 DNA contained FACT at any of the
nucleosomal sites in the promoter, we preformed ChIP assays under the
sameconditions asPanel Ausingantibodies againstH2A, FACT, andPol II
proteins.Weobserved the absence of FACT (Spt16 subunit) at the nuc-0
region upstream of the transcription start site (Panel B, top). However,
FACTwas present at low levels at the nuc-1 site in the absence of TNF-α.
Upon induction of viral transcription with TNF-α, FACT was more
328 R. Easley et al. / Virology 405 (2010) 322–333apparent on thenuc-1 aswell as the Env region (compare lanes 3 and4).
Addition of TNF-α increased the level of Pol II occupancy on both nuc-1
and Env region consistent with increased transcription. We next
performed a similar set of experiments in HLM-1 (Tat mutant) cells.
We transfected these cells with Tat to induce viral replication and
performed a ChIP assay using antibodies for H2A, FACT, and Pol II.
Recovered DNA was processed for qPCR. Enriched DNA was quantiﬁed
using anABI Prism 7100 and normalized to control empty vector HLM-1
cells. Results in panel C show that H2A ismostly removed from the nuc-
1, but not from nuc-0 or Env regions. Additionally, FACT is recruited to
the promoter region around nuc-1 when Tat is added to the system.
Collectively, these results indicate that FACT may be present on the
promoter, and the increased levels of FACT seen upon viral activation or
addition of Tat may explain the observed removal of H2A/H2B histones
from the nuc-1 region.
Presence of PBAF complex on the HIV-1 LTR and envelope region in infected
PBMC cells
To further validate our results in PBMC infection settings,we infected
freshly activated PBMCswith dual tropic 89.6 HIV-1. Cells were initially
activated with PHA+IL-2 for 4 days prior to infection with the virus.
Subsequently after infection PBMC samples were collected at days 3, 6,
and 9 and processed for ChIP. We utilized antibodies against the large
subunit of Pol II (for active transcription through HIV-1 DNA), Baf200Fig. 5. Presence of PBAF component on the HIV-1 LTR and Env regions. A) Activated PBMCs
(5×106) were collected at days 3, 6 and 9 for ChIP analysis with appropriate antibodies. Sp
speciﬁc for 89.6 strain HIV-1 LTR nuc-1 (+10 to+165) and Env (+8990 to+9120). Bottom
the RT levels in the supernatant of the cells are shown in bottom right. B) PBMC cells in day 3
both LTR and Env regions, readings were normalized to input. Lane 1 is the inputs for both L
Baf250, p300 and cdk9 ChIPs, respectively. C) Further validation of results in panel B using qP
and 9. Lane 1 represents input (1/10); lane 2 is for Baf200 and lane 3 is for Baf250 ChIPs. R(for presence of PBAF complex), Baf250 (for possible presence of BAF
complex), co-activator p300, and cdk9 which is required for Tat
activated transcription in vivo. Results are shown in Fig. 5A where
ChIP-derived DNAwas PCR ampliﬁed using LTR (nuc-1) or Env primers.
Interestingly, Pol II, cdk9, and Baf200 were present on the LTR and Env
regions from days 3–9, although less Baf200 was present on the Env
region at day 9. This indicates that Pol II, cdk9 and Baf200 complexes are
involved in transcriptional initiation and elongation. However, Baf250
andp300weremostly present on the LTR on days 3 and 6 but not onday
9. No detectable Baf250 or p300 were present on the Env region, which
re-emphasizes the notion that both of the protein complexes may be
important for transcription initiation or early proximal elongation, but
not for distal elongation. Exogenous viral RT levels gradually increased
fromday3 andpeaked at day 9. Results from the Baf250were surprising
since our previous LTR transient (Fig. 1B and C) or integrated LTR
(Fig. 3A) reporter assays showed no apparent need for the Baf250 to
obtain activated transcription. However, in an actual infection setting
(viral clone in PBMCs) Baf250 was observed on the LTR but not the Env
region. Although these results indicate the complexities of various
assays used here (LTR vs. full length virus), the presence of the SWI/SNF
PBAF complex on the LTR and Env regions clearly indicated its
involvement in transcriptional elongation on HIV-1 DNA.
To further validate the presence of the PBAF complex on the HIV-1
LTR region in activated PBMCs, chromatin association of Pol II, Baf200,
Baf250, p300 and cdk9 was quantitated using ChIP- qPCR. The qPCR in(PHA+IL-2) were infected with a dual tropic HIV-1 strain 89.6 (20,100 RT units). Cells
eciﬁc DNA sequences in the immunoprecipitates were detected by PCR, using primers
panel shows the presence of Baf200, Baf250 and actin (Western blot) in these cells. Also,
(majority of Baf200 was observed on the Env region at that time) was used for qPCR for
TR and Env region and lane 2 is for IgG control. Lanes 3–7 are results from Pol II, Baf200,
CR of the Baf200 and Baf250 ChIPs from the Env region of infected samples at days 3, 6,
eadings were normalized to input.
329R. Easley et al. / Virology 405 (2010) 322–333Panel B is from PBMC cells 3 days post infection, since the majority of
Baf200 was initially observed on the Env region at that time. Lane 1
shows inputs for both LTR and Env region and lane 2 is the IgG control
(similar to lanes 2 and 3 in panel A, respectively). Lanes 3–7 show qPCR
results from Pol II, Baf200, Baf250, p300 and cdk9 ChIPs, respectively.
Results for Baf200 (lane 4) and Baf250 (lane 5) clearly show that these
complexes are differentially loaded onto the LTR vs. Env regions.
Interestingly, the Pol II loading on LTR and Env regions (lane 3) also
shows differential loading where more Pol II loading is seen at the Env
region which may indicate that there could possibly be re-initiation of
Pol II with activated transcription.
To further validate these results, we performed qPCR of the Baf200
and Baf250 ChIPs from the Env region of infected samples at days 3, 6,
and9. Results in Panel C show thatBaf200waspresent on theEnv region
at all 3 days (lane 2) and Baf250 was completely absent on the Env
region (lane 3). It is also important to note that we have not completely
exhausted the possibility that Baf250maybe available on theEnv region
using various other antibodies or possible protein modiﬁcations
masking the epitope. Collectively, these current results suggest that
PBAF complex is involved in activated transcription and BAF complex
may only be present on the LTR for some other function, i.e., splicing.
The possible effect of BAF SWI/SNF complex on HIV-1 splicing
Our results above indicated that SWI/SNF Baf250 was present on the
promoter only, whichmay have functions other than transcription. Along
these lines, several subunits of the SWI/SNF complex including BRG1,
Baf155 and INI1 copurifywith the nuclear-receptor co-repressor complex
(NCoR), which associates with the splicing factor SF3a120 and the
spliceosome-associated protein SAP130 (Underhill et al., 2000). The PRP4
kinase can phosphorylate and interact with BRG1 and the U5 small
nuclear ribonucleoprotein particle (snRNP) subunit PRP6 (Dellaire et al.,
2002). One group has shown that human BRM favors inclusion of variant
exons in themRNA of several SWI/SNF target genes subject to alternative
splicing, independent of its chromatin remodeling activity (Batsche et al.,
2006). In addition, BRM could be immunoprecipitated with U1 and U5
snRNAs and with PRP6 and Sam68 proteins, suggesting its role in the
recruitment of the splicing machinery. BRM enters the coding region of
the CD44gene togetherwith the Pol II causing the accumulation of the Pol
II onvariant exonsof this gene. This accumulationcorrelateswithachange
in C-terminal domain (CTD) phosphorylation of the Pol II associated with
BRM. The modiﬁed pattern of CTD phosphorylation signiﬁes a halt in
elongation by the Pol II and suggested that BRM may favor inclusion of
alternative exonsbykinetically facilitating spliceosome recruitment to the
splice sites of the variant exons.
In HIV-1 infection constitutive and alternativemRNA splicing occurs
to remove upstreamGag and Pol coding sequences from the EnvmRNA
and to generate the essential regulatory proteins, Tat and Rev, aswell as
several other proteins (Vif, Vpr and Nef) needed for successful
replication in vivo. The pattern of splicing varies in accordance with
the phase of infection inHIV-1 cells.While sub-genomic species (doubly
and singly spliced) are abundant during early stages of infection, the
genomic transcripts (unspliced) appear at the later stage of infection.
The splicing of HIV-1 RNA is extremely complex because of the presence
of four 5′-splice donor sites D1 to D4 and eight 3′ splice acceptor sites
(A1, A2, A3, A4a, b, c, A5 and A7). A comprehensive study examining the
steady-state levels of viral mRNA during viral infection determined the
utilization of different splice sites for the production of the 2 and 4 kb
transcripts. A4 and A7 sites were found to be essential for the production
of Tat, A4a, b or c andA7wasused to produceRev. Nef and Env requiredA5
and Vpr required A2 sites (Purcell and Martin, 1993).
To show whether the presence of SWI/SNF (BAF or PBAF) leads to
regulation of splicing, we used an HIV-1 vector with differential splicing
patterns. In the plasmid pNLEnv, the Env gene is expressed from an
unsplicedmRNA,whereas Nef ismade froma splicedmRNA (Fig. 6A).We
transfected 293T cells with pNLEnv along with low concentrations of Tatalone or Tat and various siRNAs against BAF and PBAF. The production of
Nef and Env proteins were determined by Western blotting. Results in
Fig. 6B show that siBaf200 (knock down of the PBAF complex) increased
the presence of doubly spliced Nef, further indicating that splicing can be
detected under these conditions (Fig. 6B, lane 4). However, when using
siBaf250 (knock down of BAF complex), we observed increased levels of
Env protein. Similar levels of actin were seen in siRNA treated cells
(bottom panel). This correlated with similar RNA patterns when using
RT/PCR from these 293T transfected cells (panel C). Finally,weobserved a
similar pattern of RNA levels for both Nef and Env regions when using
HLM-1 cells treated with Tat and the two siBaf subunits (panel D).
Collectively, these results indicate that knock down of PBAF complex
increases synthesis of doubly spliced messages and consequentially the
presence of the BAF complex on the HIV-1 LTR (Fig. 5) may be important
for the regulation of splicing on the HIV-1 LTR.
Discussion
In order to free the DNA around the HIV-1 LTR, chromatin can be
opened or closed through either covalentmodiﬁcations (such asHATs) or
using theenergyofATPhydrolysis (suchasSWI/SNF). Tathasbeenshown
to interact with the HATs p300 and p/CAF, and this association could be
critical for downstream chromatin remodeling or progressive transcrip-
tional elongation. The proviral DNA can additionally be remodeled using
ATPase chromatin remodelers such as BRG1 or BRM. The SWI/SNF
complex (including the BAF and PBAF complexes) is known to play a role
in Tat transactivation, though there has been no evidence to determine if
BAF or PBAF is responsible for chromatin remodeling. Using siRNAs
against unique components of the various complexes we found that the
PBAF complexwas required for Tat activated transcription in TZM-bl cells.
We also observed the effects of acetylated versus unacetylated Tat on BAF
(Baf250) and PBAF (Baf200) and found that Baf200 bound efﬁciently to
acetylated Tat while Baf250 had very little binding in vitro. Using siRNA
against either BAFs, we found that knockdown of Baf200, but not Baf250,
suppressed Tat activated transcription in CEM cells and transfection of
Baf180 mutant cells with pNL4-3 and siBaf200 showed minimal amount
of virus production. These results collectively indicated that PBAF,
speciﬁcally the Baf200 complex, is important for Tat binding and
transactivation.
Since SWI/SNF is involved in chromatin remodeling we focused our
efforts on the nucleosomes immediately surrounding the transcription
start site.Weobserved a drop inH2AandH2B corehistone levelsmostly
in the nuc-1, and not on the Env region, further emphasizing a site
speciﬁc organization of the chromatin at the transcription start site. This
ﬁnding suggests that activated transcription could modify nuc-1
histones for Tat transactivation. Removal of H2A and H2B has
additionally been seen at the elongation site by the FACT complex,
and we hypothesized that this could also occur in HIV-1 transcription.
We observed the presence of the FACT complex at the promoter as well
as the Env region when the chromatinized virus was activated. Is it
important to note that FACT dependent transcriptionwas haultedwhen
histone polypeptides were covalently cross-linkedwithin nucleosomes,
indicating that a complex (such as an octamer) is disassembled during
activated transcription (Orphanides et al., 1999). This suggests that
FACT could possess nucleosome disassembly activity and is supported
by the interaction of Spt16 with H2A/H2B dimers (Belotserkovskaya
et al., 2003; Orphanides et al., 1999) as well as histone H3/H4's
interaction with SSRP1 (Belotserkovskaya et al., 2003).
Transcription is enhanced in vitro by the loss of H2A/H2B dimer
which is an effect of FACT-mediated transcription through the
nucleosome (Gonzalez and Palacian, 1989), additionally, the speciﬁc
loss of H2A/H2B dimers is seen during active transcription that is
mediated by Pol II in vivo (Kireeva et al., 2002). Interestingly, several
independent studies have shown that in higher organisms FACT
physically associates with CHD1 and in yeast H3K4me3 correlates
with active genes at the 5′-region and crests near the transcriptional
Fig. 6. Effects of SWI/SNF on HIV-1 splicing. A) Schematic of the pNLEnv plasmid. Env gene is expressed from an unsplicedmRNA, whereas Nef is made from a spliced mRNA. B) 293T
cells were transfected with combinations of low levels of Tat plasmid (1 μg) and siGFP, siBaf250, or siBaf200. Western blot analysis using antibodies against Nef, Env, or Actin were
performed after 3 days. Knockdown of Baf200 resulted in increased levels of Nef (spliced) protein whereas knockdown of Baf250 resulted in increased levels of Env (unspliced)
protein. Western blot of both Baf200 and 250 are shown below. C) RT/PCR of 293T transfected cells with Tat and siGFP, siBaf250, or siBaf200. One hundred nanograms of total RNA
was used for cDNA synthesis and PCR with primers for Nef and Env region. D) HLM-1 cells (7×106) were transfected with CMV-Tat (3 μg) and various siRNAs (100 nM). Total RNA
was extracted 48 h later for RT/PCR using Nef and Env primers.
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2005; Flanaganet al., 2005; Kelley et al., 1999;Kroganet al., 2002; Lusser
et al., 2005; Schneider et al., 2004; Shi et al., 1996; Simic et al., 2003; Sims
et al., 2005; Squazzo et al., 2002;Woodage et al., 1997; Yan et al., 2005).
It is likely that monoubiquitination of H2B assists in FACT mediated
removal of the H2A/H2B dimers during transcription, this is further
supported by the physical and functional interactions between FACT,
PAF and H2B modiﬁcation. This mode of targeted histone degradation
(possibly through theproteasomalATPases)maybeplayingakey role in
removal of nuc-1 histones on HIV-1 LTR. Current studies are to deﬁne
which ubiquitinated molecule(s) on the LTR (i.e., H2B) is associated
with protein degradation and which proteins in fact assist Pol II in
transcriptional elongation.
Weused a PBMC infectious setting to further observe the presence of
BAF or PBAF on the HIV-1 DNA. To our surprise we observe BAF on the
LTR but not Env region. This further indicated that the BAF complexmay
be important for events other than transcription. When looking at the
impact of BAF or PBAF on the regulation of splicing we found that
knockdown of PBAF increased the presence of doubly spliced Nef
protein while siBAF treatment increased the levels of the Env protein.
This may indicate that there are at least two stages for activated
transcription in vivo. The ﬁrst stage may utilize the BAF complex and
regulate splicing of messages by stringent recognition of the splice
acceptor anddonor sites inHIV-1 genome, a scenario similar to theCD44
gene and the accumulation of Pol II on the variant exons (as discussed
above). The second stagemay utilize PBAFwhichbinds to acetylated Tat
and recruits new set of complexes needed for repetitive and speedy Pol
II activated transcription for the entire genome.Conclusions
From our ﬁndings, it is possible to produce a newmodel of SWI/SNF's
role in HIV-1 Tat transactivation. Initiation of transcription occurs in the
presenceofunmodiﬁedTatwhichbinds toBAFandp-TEFballowingnuc-1
to become accessible. This, however, only allows for basal transcription
and an increase in splicing at theHIV-1 LTR region. In order for elongation
and rapid transcription tooccur, Tat becomes acetylated and recruits PBAF
complexes. This new complex allows for increased chromatin remodeling
followed by rapid transcription and decreased splicing to occur. The
decreased splicing is probably due to acetylated Tat binding to p32which
is an inhibitor of the splicing factor ASF/SF-2 (Berro et al., 2006). Future
experiments will deﬁne the role of these complexes on various HIV-1
clades and whether nuc-1 remodeling and RNA splicing are facilitated by
both BAF and PBAF complexes in these viruses.Materials and methods
Cell culture
HEK293T (293T) and TZM-bl cell lines were grown in Dulbecco's
modiﬁed Eagle's medium supplemented with fetal bovine serum (FBS)
(10%), 2 mM L-glutamine, and antibiotics (penicillin 100 U/ml,
streptomycin 100 mg/ml) (cDMEM). HCC1143 and CEM, cells were
grown in RPMI 1640 supplementedwith FBS, L-glutamine, and antibiotics
as described above (cRPMI). All cell lines were maintained at 37 °C in 5%
CO2.
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Human PBMCs from three healthy donors were puriﬁed by Ficoll-
Paque centrifugation and activated for 72 h with of PHA (10 μg/ml)
and recombinant human IL-2 (50 U/ml) in cRPMI medium. Freshly
activated PBMCs were infected with dual tropic 89.6 HIV-1 virus at
MOI or 10. At various time points, cell culture supernatants were
collected for ChIP assay.
GST-Tat pulldown
GST-Tat (wild-type 86 and 101) were puriﬁed over a glutathione
column and eluted. Acetylated GST-Tat (2 μg) was incubated with
p300 and acetyl-CoA (63), washed, and incubated with 100 μg of HeLa
phosphocellulose nuclear fraction (0.75 M) that contained both BAF
and PBAF complexes. Samples were incubated overnight at 4 °C in
presence of 100 ng/ml of EtBr, washed and bound complexes were
run on a 4–20% SDS/PAGE and Western blotted for the presence of
Baf200, BRG1, Baf250 and actin using speciﬁc antibodies.
Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed from cells using antibodies as
described below. Cells were seeded to 60% conﬂuency, treated as
described in the ﬁgure legends, then processed for ChIP beginning
with cross-linking proteins to DNA by 1.0% formaldehyde. Chromatin
was sonicated ﬁve times for 20 s each, generating DNA fragments of
about 500–100 base pairs. The sonicated supernatants containing the
DNA were diluted with ChIP dilution buffer (0.01% SDS, 1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl pH 8.1, and 167 mM NaCl) to
a total volume of 5.5 ml, and precleared by rotating for 1 h at 4 °C with
ChIP prepared protein A/G beads (beads washed twice with 1 ml
TNE50+NP-40, resuspend in 650 μl; add 40 μl of ssDNA (10 mg/ml)
and 75 μl BSA (10 mg/ml)). No proteases or RNAses were used for the
extraction. The extract was centrifuged at 3000 rpm for 10 min at 4 °C
and the lysate was transferred to a fresh tube. Supernatant (500 μl)
was reserved for input and then 10 μg of each antibodies indicated
above were added to the reaction mixture. After overnight rotation at
4 °C, the immune complexes were collected by addition of ChIP
prepared protein A/G beads. After extensive washes, the immune
complexes were eluted with 1% SDS/NaHCO3 solution for 30 min at
room temperature. The eluted complexes were treated with NaCl
solution and reverse cross-linked overnight. DNA was extracted using
1:1 phenol/chloroform (500 μl) followed by addition of 1 ml of
absolute ethanol and 3 M sodium acetate (50 μl) incubated at−20 °C
for at least 20–30 min. The solution was spun for 20 min at
14,000 rpm at 4 °C followed by a 70% ethanol wash and 5 min spin.
DNA pellet was resuspended in 1× TE and stored at 4 °C. Afterwards,
DNA was puriﬁed by PCR puriﬁcation Kit (BiONEER) and ampliﬁed by
PCR. For qPCR, enriched DNA was also quantiﬁed using an ABI Prism
7100 instrument and SYBR green (Applied Biosystems, Foster City, CA,
USA). Primer pairs for quantitative-PCR analysis of chromatin
immunoprecipitation ampliﬁed sequences ﬂanked the HIV-1 LTR
nuc-1 (+10 to +165) and Env (+8990 to +9120). For qPCR,
enriched DNAwas also quantiﬁed using an ABI Prism 7100 instrument
and SYBR green (Applied Biosystems). Primer pairs for quantitative-
PCR analysis of chromatin immunoprecipitation ampliﬁed sequences
ﬂanked the HIV-1 LTR nuc-0 (−415 to −255, nuc-1 (+10 to +165)
and Env (+8990 to +9120). Readings were normalized to either Tat
deﬁcient samples or input as speciﬁed in the ﬁgure legend.
Antibodies
Antibodies used were obtained from Upstate Biotech (H2A, 07-
146; H2B, 07-371; H3, 04-801; and H4, 05-858) and Santa Cruz
(Baf200, sc81050; Baf250, sc48791; SPT16, sc28734; p300, sc584;BRG1, sc10768; and Actin, 7210). The Pol II (8WG16 against the
unphosphorylated CTD) has previously been used by us for many ChIP
assays. Cdk9 antibody was from Biodesign. The following reagent was
obtained through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: Nef (2949) and Env gp160 (1209).CAT assays
CEM cells were transfected (electroporation) with HIV-LTR-CAT
(5 μg), CMV-Tat (3 μg), and 20 nM (or higher concentrations) of
either siBaf200 or siBaf250. After 48 h, cells were lysed and
chloramphenicol acetyltransferase (CAT) activity was determined. A
standard reaction was performed by adding the cofactor acetyl
coenzyme A to a microcentrifuge tube containing cell extract and
radiolabeled (14C) chloramphenicol in a ﬁnal volume of 50 μl and
incubating the mixture at 37 °C for 1 h. The reactionmixture was then
extracted with ethyl acetate and separated by thin-later chromatog-
raphy on silica gel plates (Bakerﬂex silica gel thin-later chromatog-
raphy plates) in a chloroform–methanol (19:1) solvent. The resolved
reaction products were then detected by exposing the plate to a
PhosphorImager cassette.Western blots
Cell extracts were resolved by SDS PAGE on a 4–20% tris-glycine gel
(Invitrogen). Proteins were transferred to Immobilon membranes
(Millipore) at 200 mA for 2 h. Membranes were blocked with Dulbecco's
phosphate-buffered saline (PBS) 0.1% Tween-20+5% BSA. Primary
antibody against speciﬁed antibodies was incubated with the membrane
inPBS+0.1%Tween-20overnight at 4 °C.Membraneswerewashed three
times with PBS+0.1% Tween-20 and incubated with HRP-conjugated
secondary antibody for 1 h. Presence of secondary antibodywas detected
by SuperSignal West Dura Extended Duration Substrate (Pierce).
Luminescence was visualized on a Kodak 1D image station.siRNA Treatment
BRG1 (sc29827), BRM (sc29831), Baf200 (sc96225), and Baf250
(sc43628) siRNAs were purchased from Santa Cruz Biotechnology Inc.
siGENOME SMART pool for PB1 (Baf180) (M-008692-01-0005) was
purchased from Dharmacon. siRNA (at various concentrations) was
transfected into cells using Attractene (Qiagen) according to the
manufacturer's instructions.Transfections and RT assays
HCC1143 cellswere seeded in 6well plates at 400,000 cells/well and
then transfected with 20 μg of pNL4-3 either alone or with 30 nM of
siBaf200 using Attractene (Qiagen). Supernatants were collected to test
for the presence of virus on days 2, 3, and 4. Viral supernatants (10 μl)
were incubated in a 96-well plate with reverse transcriptase (RT)
reaction mixture containing 1× RT buffer (50 mM Tris–HCl, 1 mMDTT,
5 mM MgCl2, 20 mM KCl), 0.1% Triton, poly(A) (1 U/ml), pd(T) (1 U/
ml), and [3H]TTP. The mixture was incubated overnight at 37 °C, and
10ml of the reaction mix was spotted on a DEAE Filtermat paper,
washed four times with 5% Na2HPO4 and three times with water, and
then dried completely. RT activity was measured in a Betaplate counter
(Wallac, Gaithersburg, MD). Cells (day 4) were also processed for
Western blot analysis using anti-Baf200 and anti-actin antibodies.Competing interests
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